The randomized NLST had shown that three rounds of annual screening with low-dose CT reduced lung cancer mortality by 20% among current and former smokers as compared with the same number of annual ...
Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depend on the ability to deliver tiny particles known as aerosols to the correct location in ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study
This pathology is largely undiagnosed within existing TB management pathways, but is meaningful for patient outcomes, with accelerated lung function decline, ongoing respiratory-related health seeking ...
Lung cancer was the fifth largest leading cause of cancer deaths worldwide for those who have never smoked Vanessa Etienne is an Emerging Content Writer-Reporter for PEOPLE. Getty The proportion ...
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. The Waltham, Massachusetts-based company already unveiled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback